scholarly journals Augmentation of implant surfaces with BMP-2 in a revision setting

2021 ◽  
Vol 10 (8) ◽  
pp. 488-497
Author(s):  
Rasmus Cleemann ◽  
Mette Sorensen ◽  
Andreas West ◽  
Kjeld Soballe ◽  
Joan E. Bechtold ◽  
...  
Keyword(s):  
Bone Graft ◽  
Revision Surgery ◽  
Bone Morphogenetic Protein 2 ◽  
Anabolic Effect ◽  
Implant Fixation ◽  
Implant Surface ◽  
Anabolic Agent ◽  
Morphogenetic Protein ◽  
Group 12 ◽  
Load To Failure

Aims We wanted to evaluate the effects of a bone anabolic agent (bone morphogenetic protein 2 (BMP-2)) on an anti-catabolic background (systemic or local zoledronate) on fixation of allografted revision implants. Methods An established allografted revision protocol was implemented bilaterally into the stifle joints of 24 canines. At revision surgery, each animal received one BMP-2 (5 µg) functionalized implant, and one raw implant. One group (12 animals) received bone graft impregnated with zoledronate (0.005 mg/ml) before impaction. The other group (12 animals) received untreated bone graft and systemic zoledronate (0.1 mg/kg) ten and 20 days after revision surgery. Animals were observed for an additional four weeks before euthanasia. Results No difference was detected on mechanical implant fixation (load to failure, stiffness, energy) between local or systemic zoledronate. Addition of BMP-2 had no effect on implant fixation. In the histomorphometric evaluation, implants with local zoledronate had more area of new bone on the implant surface (53%, p = 0.025) and higher volume of allograft (65%, p = 0.007), whereas implants in animals with systemic zoledronate had the highest volume of new bone (34%, p = 0.003). Systemic zoledronate with BMP-2 decreased volume of allograft by 47% (p = 0.017). Conclusion Local and systemic zoledronate treatment protects bone at different stages of maturity; local zoledronate protects the allograft from resorption and systemic zoledronate protects newly formed bone from resorption. BMP-2 in the dose evaluated with experimental revision implants was not beneficial, since it significantly increased allograft resorption without a significant compensating anabolic effect. Cite this article: Bone Joint Res 2021;10(8):488–497.

scholarly journals Surface Immobilization of TiO2 Nanotubes with Bone Morphogenetic Protein-2 Synergistically Enhances Initial Preosteoblast Adhesion and Osseointegration

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Ying Li ◽  
Yunjia Song ◽  
Aobo Ma ◽  
Changyi Li
Keyword(s):  
Bone Morphogenetic Protein ◽  
Bone Morphogenetic Protein 2 ◽  
Surface Immobilization ◽  
Implant Surface ◽  
Cytoskeleton Organization ◽  
Morphogenetic Protein ◽  
Human Bone Morphogenetic Protein ◽  
Collagen Type 1

Although titanium (Ti) alloys have been widely used as implant materials, the bioinertness of pristine Ti impairs their bioactivity and early osseointegration. In the present work, we prepared TiO2 nanotubes (TNT) layer on the titanium (Ti) surface by anodic oxidation. The anodized surface was functionalized with human bone morphogenetic protein-2 coating to form the hBMP-2/TNT surface. The release behavior of hBMP-2 on the hBMP-2/TNT surface displayed a controlled and sustained pattern, compared to that on the hBMP-2/Ti surface, which showed a rapid release. In vitro cellular activity tests demonstrated that both TNT and hBMP-2/Ti surfaces, particularly the hBMP-2/TNT surface, enhanced adhesion, proliferation, and differentiation of osteoblast cells. Increased cell adhesion, improved cytoskeleton organization, and immunofluorescence staining of vinculin were observed on the modified surfaces. The TNT, hBMP-2/Ti, and hBMP-2/TNT surfaces, especially the hBMP-2/TNT surface, further displayed an upregulated gene expression of adhesion and osteogenic markers vinculin, collagen type 1, osteopontin, and osteocalcin, compared to the pristine Ti surface. In vivo experiments using a rat model demonstrated that the TNT and hBMP-2/Ti surfaces, in particular the hBMP-2/TNT surface, improved osseointegration and showed a superior bone bonding ability compared to Ti. Our study revealed a synergistic role played by TiO2 nanotubes nanotopography and hBMP-2 in promoting initial osteoblast adhesion, proliferation, differentiation, and osseointegration, thus suggesting a promising method for better modifying the implant surface.

Delivery Mode and Efficacy of BMP-2 in Association with Implants

2007 ◽  
Vol 86 (1) ◽  
pp. 84-89 ◽  
Author(s):  
Y. Liu ◽  
R.O. Huse ◽  
K. de Groot ◽  
D. Buser ◽  
E.B. Hunziker
Keyword(s):  
Calcium Phosphate ◽  
Bone Matrix ◽  
Bone Morphogenetic Protein 2 ◽  
Calcium Phosphate Coating ◽  
Delivery Mode ◽  
Implant Surface ◽  
Morphogenetic Protein ◽  
Mode Of Application ◽  
Mineralized Bone Matrix ◽  
Implant Coatings

Bone healing may be improved in implant patients by the administration of osteogenic agents, such as bone morphogenetic protein 2 (BMP-2). But the efficacy of BMP-2 depends upon its mode of application. We hypothesized that BMP-2 is capable of a higher osteogenic efficacy when delivered physiologically, viz., when incorporated into a calcium-phosphate carrier that mimics mineralized bone matrix, than when administered via simple pharmacological modes, such as by adsorption onto a carrier surface. Using an ectopic rat model, we compared the osteoinductive efficacies of calcium-phosphate implant-coatings bearing either incorporated, adsorbed, or incorporated and adsorbed BMP-2. When adsorbed directly onto the naked implant surface, BMP-2 was not osteogenic. When adsorbed onto a calcium-phosphate coating, it was osteoinductive, but not highly efficacious. When BMP-2 was incorporated into calcium-phosphate coatings, it was a potent bone-inducer, whose efficacy was compromised, not potentiated, by the additional deposition of an adsorbed pool.

Potential of bone scaffolds containing vancomycin and bone morphogenetic protein-2 in a rat model of osteomyelitis

2014 ◽  
Vol 8 (5) ◽  
pp. 651-658 ◽  
Author(s):  
Suphannee Thanyaphoo ◽  
Jasadee Kaewsrichan
Keyword(s):  
Calcium Phosphate ◽  
Bone Graft ◽  
Bone Morphogenetic Protein ◽  
Rat Model ◽  
Drug Carrier ◽  
Bone Diseases ◽  
Bone Morphogenetic Protein 2 ◽  
Bone Scaffolds ◽  
Morphogenetic Protein ◽  
Antibiotic Drug

Abstract Background: Infected bone is often intractable. An ideal approach is to simultaneously eradicate infection and repair the bone defect. The development of osteoinductive bone graft composites to control antibiotic drug release would be useful for the treatment of intractable bone infections. Objectives: To develop a rat model of osteomyelitis for assessing osteoinductive bone graft scaffolds containing antibiotics and a bone morphogenetic protein. Methods: Si-imprinted calcium phosphate is a new hydroxyapatite derivative used in fabricating bone scaffolds. Vancomycin and bone morphogenetic protein-2 (BMP-2) were loaded onto scaffolds of Si-imprinted calcium phosphate using an established method. The efficiency of the scaffold as a drug carrier system was assessed in vivo. Osteomyelitis was induced in rats by infection of the tibial epiphysis with Staphylococcus aureus (BAA 1680). The success of inducing disease was checked after 4 weeks using bacterial culture and radiography. A 10 mm metaphysis bone was surgically removed and replaced with a drug-loaded scaffold. Histology and X-ray imaging were used to evaluate the implants at 8 weeks post implantation. Results: We successfully established a rat model of osteomyelitis. The causative bacteria were effectively eradicated by vancomycin released from the implants. Enhanced bone formation was observed for the implant samples containing vancomycin and BMP-2 compared with those containing either vancomycin or BMP2 alone. Conclusions: The newly developed bone scaffold has potential as a vehicle for therapeutic agents to treat bone diseases.

Sign in / Sign up

Export Citation Format

Share Document